Breceptin

Drug Profile

Breceptin

Alternative Names: B201; B201-acetate

Latest Information Update: 29 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ApopLogic Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Bradykinin B1 receptor antagonists; Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-small cell lung cancer; Prostate cancer

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 29 Aug 2016 Preclinical development is underway for Solid tumours in USA.
  • 25 Aug 2016 Breceptin is available for licensing as of 25 Aug 2016. http://www.apoplogic.com/
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top